 MedIndia | EASD: Debate Brings Incretin Risks to Forefront MedPage Today The findings were based on an analysis of data from the FDA's Adverse Event Reporting System (AERS), which is known to have several limitations, as pointed out by debate opponent Michael Nauck, MD, of the Diabetes Center Bad Lauterberg in Harz, … Possible link between diabetes drugs, cancer Two diabetes drugs linked to pancreatitis, cancer Possible Link Between Two Diabetes Drugs and Pancreatic Cancer |
EASD: Debate Brings Incretin Risks to Forefront – MedPage Today
September 18, 2011
